AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment corresponding to amino acids 177-191 of human growth hormone (hGH), with an additional tyrosine residue at the N-terminus for enhanced stability. This 16-amino acid peptide was originally developed as a targeted approach to studying the lipolytic properties of growth hormone without the metabolic side effects associated with full-length hGH administration.

Research indicates AOD-9604 selectively activates the AMP-activated protein kinase (AMPK) pathway and interacts with beta-3 adrenergic receptors in adipose tissue, promoting lipolysis (the breakdown of stored triglycerides into free fatty acids) while simultaneously inhibiting lipogenesis (new fat synthesis). Critically, unlike full-length hGH, AOD-9604 does not appear to affect blood glucose levels or IGF-1 concentrations in preclinical studies, suggesting tissue-specific metabolic activity.

Pure Pharm Peptides' AOD-9604 is verified at 99.179% purity, making it suitable for rigorous metabolic research protocols requiring consistent peptide quality.

Research Applications:

• Adipose tissue lipolysis and lipogenesis pathway studies
• AMPK signaling in metabolic regulation research
• Beta-3 adrenergic receptor pharmacology investigations
• Selective hGH domain activity dissection studies
• Body composition and fat metabolism research models
• Comparative studies vs. full-length hGH metabolic effects

Key Specifications:

• Purity: 99.179% verified by Freedom Diagnostics testing
• Dosage: 5mg per vial
• Category: Weight Loss
• Storage: -20°C or colder (lyophilized)
• Stability: Up to 2 years when stored properly

Research Highlights:

• 99.179% purity verified by Freedom Diagnostics HPLC analysis
• Derived from hGH residues 177-191 — the lipolytic domain of growth hormone
• Selective adipose tissue effects without IGF-1 or glucose metabolism changes
• AMPK pathway activation and beta-3 adrenergic receptor interaction
• Molecular weight: 1,815.1 Da | CAS: 221231-10-3 | PubChem CID: 71300630